Publications by authors named "A Melotti"
Article Synopsis
- Human pegivirus-1 (HPgV-1) is a virus that doesn’t cause disease but may influence immune recovery in people undergoing hematopoietic stem cell transplants (allo-HSCT), especially in those with HIV co-infection.
- The study compared the immune reconstitution of two groups of allo-HSCT patients, one group with HPgV-1 and another without, analyzing T and NK cell recovery over a year.
- Results showed no significant differences in T cell counts between groups, but HPgV-1-viremic patients had higher NK cell counts and exhibited distinct NK cell characteristics, suggesting that HPgV-1 may impact immune cell differentiation post-transplant.
CD4+FOXP3+ regulatory T cells (Tregs) have demonstrated efficacy in the prevention and treatment of graft-versus-host disease (GVHD). Preclinical and clinical studies indicate that Tregs are able to protect from GVHD without interfering with the graft-versus-tumor (GVT) effect of hematopoietic cell transplantation (HCT), although the underlying molecular mechanisms are largely unknown. To elucidate Treg suppressive function during in vivo suppression of acute GVHD, we performed paired T-cell receptor (TCRα and ΤCRβ genes) repertoire sequencing and RNA sequencing analysis on conventional T cells (Tcons) and Tregs before and after transplantation in a major histocompatibility complex -mismatched mouse model of HCT.
View Article and Find Full Text PDFBackground: SOUNDS strengthens the evidence basis of sacral neuromodulation (SNM) for overactive bladder (OAB) through real-world data.
Objective: To analyze diary-based effectiveness, quality of life (QoL), disease severity, symptom bother, and safety data for SNM with the InterStim system up to 3 yr after implantation.
Design, Setting, And Participants: Twenty-five representative French sites enrolled 291 patients with OAB followed according to the local standard of care.
Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Eur Urol Focus
November 2021
Background: Real-world data that support the use of sacral neuromodulation (SNM) for lower urinary tract dysfunctions are of continued interest.
Objective: To evaluate the effectiveness, quality of life (QoL), patient-reported outcomes (PROs), and safety of SNM with the InterStim™ system in real life during 1-yr postimplant.
Design, Setting, And Participants: This is a prospective, multicenter, observational study at 25 representative public and private French sites.